Synergistic Antiviral Activity of Xanthan Gum and Camostat Against Influenza Virus Infection
Viruses · 2025
DOI: 10.3390/v17030301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Kyeunghwa Chun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Daewoong Pharmaceutical Co., Ltd., 72, Dugye-ro, Pogok-eup, Cheoin-gu, Yongin-si 17028, Gyeonggi-do, Republic of Korea. Hauptthemen laut MEDLINE: Polysaccharides, Bacterial, Antiviral Agents, Orthomyxoviridae Infections, Influenza A virus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Influenza A virus (IAV) is a major cause of respiratory infections worldwide. Current preventive measures, though effective for decades, face limitations due to the continuous evolution of viral strains and challenges in targeting specific viral proteins. In this study, we conducted in vivo screenings to evaluate the antiviral properties of various promising polymers to overcome the limitations of current virus infection prevention strategies. Subsequently, we performed detailed physiological and pathological assessments over an extended infection period. In the animal experiments regarding weight loss, a key symptom of viral infection, the group treated with xanthan gum (XG) showed significant suppression of weight loss compared to the untreated group starting from 3 DPI. Throughout the experiment, the treated group maintained a body weight similar to that of the uninfected group. In the virus titration and lung tissue pathology analysis, the group treated with the test substance showed a significantly lower viral load and tissue pathology results closer to normal compared to the untreated group. Additionally, we conducted in vitro combination treatment experiments to evaluate the antiviral ability of XG in conjunction with camostat, a previously known TMPRSS2 inhibitor. The results demonstrated that in the combination-treated groups, XG and camostat exhibited significantly higher cell viability at lower concentrations compared to the single-treatment groups for influenza A H1N1, A H3N2, and B type. These results indicate that XG possesses potential capabilities in inhibiting respiratory viruses and may be utilized in conjunction with existing antiviral treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Daewoong Pharmaceutical Co., Ltd., 72, Dugye-ro, Pogok-eup, Cheoin-gu, Yongin-si 17028, Gyeonggi-do, Republic of Korea.
- College of Pharmacy, Pusan National University, 2, Busandaehak-ro 63beon-gil, Geumjeong-gu, Busan 46241, Republic of Korea.
- Major of Biohealth Regulatory Science, School of Liberal Studies, Kunsan National University, 558 Daehak-ro, Gunsan 54150, Jeollabuk-do, Republic of Korea.
ORCID-Profile: Byeongyong Kim, Gwanyoung Kim
Zitieren
APA
Chun, K., Na, Y., Kim, B., Lee, D., Choi, J., Kim, G., Kim, S., & Kim, M. S. (2025). Synergistic Antiviral Activity of Xanthan Gum and Camostat Against Influenza Virus Infection. Viruses. https://doi.org/10.3390/v17030301
Vancouver
Chun K, Na Y, Kim B, Lee D, Choi J, Kim G, et al. Synergistic Antiviral Activity of Xanthan Gum and Camostat Against Influenza Virus Infection. Viruses. 2025. doi:10.3390/v17030301
BibTeX
@article{Chun2025,
author = {Chun, Kyeunghwa and Na, Yujeong and Kim, Byeongyong and Lee, Dongjin and Choi, Jongseo and Kim, Gwanyoung and Kim, Sokho and Kim, Min-Soo},
title = {Synergistic Antiviral Activity of Xanthan Gum and Camostat Against Influenza Virus Infection},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17030301}
}
EUVIMED